Clinical Trials Logo

Clinical Trial Summary

Bullous pemphigoid (BP) is the most common of the autoimmune blistering skin diseases in Western Europe. [Joly 2012]The study will recruit the new onset or relapsing mild to moderate BP patients. The study population will consist of patients above the age of 18 years with an active episode of BP, confirmed by inclusion and exclusion criteria and who, in the opinion of the Investigator, would benefit from treatment with rVA576. Recombinant rVA576 is a small protein complement C5 and LTB4 inhibitor, which prevents the cleavage of C5 by C5 convertase and thereby inhibits generation of C5b-9 the membrane attack complex (MAC), as well as preventing the release of the anaphylatoxin C5a. rVA576 is effective in inhibiting terminal complement activity irrespective of the activating pathway (classical, lectin or alternative). This Phase IIa open-label single-arm study will evaluate the safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid patients


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04035733
Study type Interventional
Source AKARI Therapeutics
Contact
Status Completed
Phase Phase 2
Start date September 25, 2018
Completion date April 29, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06371417 - Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Phase 1
Completed NCT02502903 - Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders Phase 1